Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVG Chemotherapy for Stage I and II Hodgkin's Lymphoma
NCT00086801Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2004
- Primary completion
- Mar 2007
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, vinblastine and gemcitabine in Hodgkin lymphoma (HL), sponsored by Cancer and Leukemia Group B. Primary endpoint: Complete Response Rate at 24 weeks. Started May 2004; status: completed.
02
Drugs
pegylated liposomal doxorubicinvinblastinegemcitabine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00086801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086801.